These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1815534)

  • 1. Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator.
    Tanswell P; Seifried E; Stang E; Krause J
    Arzneimittelforschung; 1991 Dec; 41(12):1310-9. PubMed ID: 1815534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
    Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.
    Seifried E; Tanswell P; Ellbrück D; Haerer W; Schmidt A
    Thromb Haemost; 1989 Jun; 61(3):497-501. PubMed ID: 2508258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocytosis of the recombinant tissue plasminogen activator alteplase by hepatic endothelial cells.
    Seydel W; Stang E; Roos N; Krause J
    Arzneimittelforschung; 1991 Feb; 41(2):182-6. PubMed ID: 1904231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue plasminogen activator: a new thrombolytic agent.
    Crabbe SJ; Cloninger CC
    Clin Pharm; 1987 May; 6(5):373-86. PubMed ID: 3117481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans.
    Verstraete M; Bounameaux H; de Cock F; Van de Werf F; Collen D
    J Pharmacol Exp Ther; 1985 Nov; 235(2):506-12. PubMed ID: 4057083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human].
    Seifried E; Böck F; Tanswell P; Rijken DC; Kluft C; Heimpel H
    Klin Wochenschr; 1988; 66 Suppl 12():40-9. PubMed ID: 2450222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.
    Tanswell P; Heinzel G; Greischel A; Krause J
    J Pharmacol Exp Ther; 1990 Oct; 255(1):318-24. PubMed ID: 2120422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis.
    Marder VJ; Brenner B; Totterman S; Francis CW; Rubin R; Rao AK; Kessler CM; Kwaan HC; Sharma GV; Fong KL
    J Lab Clin Med; 1992 May; 119(5):485-95. PubMed ID: 1583404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
    van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
    Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers.
    Seifried E; Tanswell P; Rijken DC; Barrett-Bergshoeff MM; Su CA; Kluft C
    Arzneimittelforschung; 1988 Mar; 38(3):418-22. PubMed ID: 3132929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator.
    de Boer A; Kluft C; Kroon JM; Kasper FJ; Schoemaker HC; Pruis J; Breimer DD; Soons PA; Emeis JJ; Cohen AF
    Thromb Haemost; 1992 Jan; 67(1):83-7. PubMed ID: 1615490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
    De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
    Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total body and hepatic clearance in rats of recombinant tissue-type plasminogen activator expressed in mouse C127 and Chinese hamster ovary cells.
    Hori R; He YL; Shima T; Inui K; Aoki S; Okumura K; Tanigawara Y
    Drug Metab Dispos; 1992; 20(4):541-6. PubMed ID: 1356732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats.
    van der Kaaden ME; Rijken DC; Kruijt JK; van Berkel TJ; Kuiper J
    Thromb Haemost; 1997 Apr; 77(4):710-7. PubMed ID: 9134648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.